Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Investing.com -- Glaukos Corporation (NYSE:GKOS) reported better-than-expected first quarter results on Thursday, but shares tumbled 8.8% as the company’s full-year revenue guidance failed to impress investors.
The ophthalmic pharmaceutical and medical technology company posted adjusted earnings per share of -$0.22 for Q1 2025, beating analyst estimates of -$0.35. Revenue came in at $106.7 million, surpassing the consensus forecast of $102.5 million and representing a 25% YoY increase.
Glaukos reaffirmed its full-year 2025 revenue guidance of $475 million to $485 million, in line with analyst expectations of $479.9 million. However, the outlook appears to have disappointed investors, leading to the sharp decline in the stock price.
The company’s Q1 performance was driven by strong growth in its glaucoma segment, which saw record net sales of $88.1 million, up 31% YoY. U.S. glaucoma sales were particularly robust, increasing 41% YoY to $59.1 million.
"Our record first quarter results reflect a strong start to the year and sustained growth acceleration in our business driven by successful global execution of our key strategic plans," said Thomas Burns, Glaukos chairman and chief executive officer.
Glaukos reported a gross margin of approximately 77% for the quarter, with non-GAAP gross margin at 82%. The company ended Q1 with $303.4 million in cash, cash equivalents, short-term investments, and restricted cash, and no debt.
Despite the positive quarterly results, the market’s negative reaction suggests investors may have been looking for more aggressive guidance or additional catalysts to drive future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.